cor2ed
engage checkpoint medical linkedin twitter
bg

SIRT or sorafenib in patients with locally advanced HCC: SARAH and SIRveNIB trials

SIRT or sorafenib in patients with locally advanced HCC: SARAH and SIRveNIB trials

Dr. Mohamed Bouattour

Dr. Mohamed Bouattour from Hôpital Beaujon, APHP Clichy, France, discusses the SARAH and SIRveNIB trials in locally advanced HCC
Portrait of Mohamed Bouattour
Dr. Mohamed Bouattour

Hepatologist and Gastroenterologist

Beaujon University Hospital

France

preview next

time Expert View | open 5 min | 2017

download resources

I agree that this educational programme:

HCC CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and from Eisai Europe Limited.

Other programmes of interest

preview next